Evidence map›Paper›PMID 18505928›Full record

ArticleMolecular cancer research : MCR2008

Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene.

Hui-Wen Lo, Lisa Stephenson, Xinyu Cao, Mira Milas, Raphael Pollock, Francis Ali-Osman

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. A multi-scale integrated analysis identifies KRT8 as a pan-cancer early biomarker.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. CLDN6 promotes chemoresistance through GSTP1 in human breast cancer.Journal of experimental & clinical cancer research : CR · 2017
    Article
  11. Article
  12. Article
  13. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Hui-Wen LoDepartment of Surgery, Duke University Comprehensive Cancer Center, 421 MSRB I, 103 Research Drive, Durham, NC 27710, USA.
Lisa Stephenson
Xinyu Cao
Mira Milas
Raphael Pollock
Francis Ali-Osman
Duke University · USSociety of Surgical Oncology · USThe University of Texas MD Anderson Cancer Center · US

Funding

TEMODAR RESISTANCE IN CENTRAL NERVOUS SYSTEMP50CA108786 · NCI · DUKE UNIVERSITY · PI BIGNER, DARELL D · 2004 to 2009
$12.3M
Novel Targeted Therapeutics for CNS MalignanciesR01CA112519 · NCI · DUKE UNIVERSITY · PI ALI-OSMAN, FRANCIS · 2006 to 2010
$1.7M
Protein Kinase C and GSTP1 interactions in glioma drug resistanceR01CA127872 · NCI · DUKE UNIVERSITY · PI ALI-OSMAN, FRANCIS · 2008 to 2012
$1.6M
Nuclear EGFR Signaling Network in Human CancerK01CA118423 · NCI · DUKE UNIVERSITY · PI LO, HUI-WEN · 2006 to 2010
$713k
NCI NIH HHS 1K01-CA118423-01NCI NIH HHS K01 CA118423NCI NIH HHS P50 CA108786NCI NIH HHS P50CA108786-01NCI NIH HHS R01 CA112519NCI NIH HHS R01CA112519NCI NIH HHS R01 CA127872
6 · The paper itself

Abstract

The glutathione S-transferase P1 (GSTP1) is involved in multiple cellular functions, including phase II metabolism, stress response, signaling, and apoptosis. The mechanisms underlying the significantly high GSTP1 expression in many human tumors are, however, currently not well understood. We report here that the GSTP1 gene is a heretofore unrecognized downstream transcriptional target of the tumor suppressor p53. We identified a p53-binding motif comprising two consecutive half-sites located in intron 4 of the GSTP1 gene and is highly homologous to consensus p53-binding motifs in other p53-responsive genes. Using a combination of electrophoretic mobility shift assay and DNase I footprinting analyses, we showed that wild-type p53 protein binds to the GSTP1 p53 motif and luciferase reporter assays showed the motif to be transcriptionally functional in human tumor cells. In a temperature-sensitive p53-mutant cells, levels of both p21/WAF1 and GSTP1 gene transcripts increased time dependently when cells were switched from the inactive mutant state to the wild-type p53 state. Small interfering RNA-mediated reduction of p53 expression resulted in a specific decrease in GSTP1 expression and in tumor cells with mutated p53; adenovirally mediated expression of wild-type p53 increased GSTP1 expression significantly. In a panel of early-passage brain tumor cultures from patients, high levels of GSTP1 transcripts and protein were associated with wild-type p53 and, conversely, low GSTP1 levels with mutant p53. p53 expression knockdown by small interfering RNA increased cisplatin sensitivity. The ability of wild-type p53 to transcriptionally activate the human GSTP1 gene defines a novel mechanism of protecting the genome and, potentially, of tumor drug resistance.

Indexed as

Gene Expression Regulation, NeoplasticGenes, Tumor SuppressorTranscription, GeneticAmino Acid MotifsBase SequenceBinding SitesBrain NeoplasmsCell Line, TumorCisplatinDrug Resistance, NeoplasmGenes, p53Glutathione S-Transferase piHumansMolecular Sequence DataMutationTumor Suppressor Protein p53CisplatinGlutathione S-Transferase piTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID18505928
PMCPMC2570202
OpenAlexW2145483085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.